Maartje Hooning

Maartje Hooning serves as Associate Professor in the Department of Medical Oncology at Erasmus University Medical Center (Erasmus MC) in Rotterdam, Netherlands. Her research focuses on hereditary breast and ovarian cancer syndromes, particularly among BRCA1/2 pathogenic variant carriers, with emphasis on risk assessment, prevention strategies, and long-term health outcomes following cancer treatments.

Her primary research interests include breast cancer genetics, ovarian cancer prevention through risk-reducing salpingo-oophorectomy, cardiovascular health in cancer survivors, and pharmacogenomics of breast cancer therapies. She investigates how genetic predispositions interact with cancer treatments to influence long-term morbidity, particularly cardiovascular complications in high-risk populations.

Analysis of her 2025 publications reveals a strong interdisciplinary focus bridging oncology, cardiology, and genetics. Key themes include cardiovascular risk assessment after risk-reducing surgeries, post-surgical cancer occurrence patterns in BRCA carriers, and genetic factors influencing treatment response. This work demonstrates her commitment to optimizing survivorship care through precision medicine approaches for hereditary cancer populations.

Scientific Recognition: No specific awards were documented in the provided materials.

Academic Leadership: Dr. Hooning has supervised 3 research projects or students. She maintains active collaboration within the Hereditary Breast and Ovarian Cancer Research Group Netherlands (HEBON), contributing to national consortia studying genetic and environmental factors in breast and ovarian cancer. Her research integrates clinical oncology with cardiovascular medicine to address critical survivorship issues.

Research Infrastructure: As a core member of HEBON, she participates in large-scale genomic and epidemiological studies. Her work leverages multi-institutional collaborations across Dutch academic medical centers to investigate cancer risk prediction models and long-term treatment outcomes in genetically predisposed populations.